A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

Active:	No
Cancer Type:	Solid Tumor Unknown Primary	NCT ID:	NCT04762602
Trial Phases:	Phase I	Protocol IDs:	2020-306-GLOB2 (primary) NCI-2021-01982
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Hutchmed
NCI Full Details:	http://clinicaltrials.gov/show/NCT04762602

Summary

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and
preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.

Objectives

HMPL-306 is a dual IDH1/2 inhibitor

This is a phase 1, open-label, multicenter study to evaluate the safety and tolerability of
HMPL-306 administered orally in the treatment of subjects with advanced or metastatic solid
tumors with IDH mutation. The study consists of 2 parts: Part 1 (dose escalation) and Part 2
(dose expansion). The dose escalation part will determine the MTD/RP2D. The dose expansion
part will administer the MTD/RP2D to mIDH-positive solid tumor malignancies including, but
not limited to, cholangiocarcinoma, skeletal chondrosarcoma, low-grade glioma, perioperative
low-grade glioma

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.